Arbutus Biopharma Corp
Gesloten
4.25 -1.85
Overzicht
Wijziging aandelenprijs
24u
Min
4.17
Max
4.33
Inkomsten | 4M -3.8M |
|---|---|
Verkoop | 522K 1.1M |
EPS | -0.014 |
Winstmarge | -357.374 |
Werknemers | 19 |
EBITDA | 75K -7.6M |
Volgende Winsten | 5 aug 2026 |
|---|
Marktkapitalisatie | 26M 865M |
|---|---|
Vorige openingsprijs | 6.1 |
Vorige sluitingsprijs | 4.25 |
Technische score
By Trading Central
Vertrouwen
Weak Bearish Evidence
Arbutus Biopharma Corp Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Arbutus Biopharma Corp Prognose
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
